ALPS Equal Sector Weight

SEVEN HILLS RLTY TR COM USD0.001 (S/R 04/12/2025)

SMX Security Matters

Polyrizon

Picard Medical

Synchronoss Tech

PharmaCyte Biotech

Q/C Tech

Rich Sparkle

Hoyne Bancorp

Tradr 2X Long ASTS Daily ETF

EQL Pharma AB :EQL PHARMA RECRUITS ALLAN SYLVEST AASBERG AS NEW CHIEF FINANCIAL OFFICER (CFO) ALLAN SYLVEST AASBERG WILL JOIN AS NEW CFO EARLY APRIL 2026CURRENT CFO ANNA JÖNSSON TO BECOME HEAD OF ACCOUNTING

Reuters

EQL Pharma Recruits Allan Sylvest Aasberg As New CFO

DNB Carnegie has published a new commissioned research report on EQL Pharma.To access the full report and subscribe to future updates, visit

Modular Finance Ab

DNB Carnegie Access: EQL Pharma: Temporary softness in Q2 as visibility recovers – Q2 preview

EQL Pharma has reported delivery delays from suppliers in Q2, leading to lost sales and a weaker outlook for the full year 2025/26, with expected growth closer to 15% instead of 30%. Sales for Q2 are projected to be just under 90 MSEK, reflecting single-digit growth year-over-year. The EBITDA margin is anticipated to be around 20%. Launches planned for Q2 are postponed to late Q3 or early Q4. The company reassures that these issues are temporary and do not impact its five-year targets. Full results will be disclosed on November 5, 2025.

Delivery delays mean that the second quarter and thus the full year 2025/26 will be weaker than expected

Zacks Commentary

Should ALPS Equal Sector Weight ETF  ( EQL )  Be on Your Investing Radar?

The Invesco S&P 500 Equal Weight Swap UCITS ETF announced its net asset value (NAV) per share as of August 29, 2025, at USD 5.1158. The total number of shares in issue is 77,572,565. This information is provided by RNS, the news service of the London Stock Exchange, which is approved by the Financial Conduct Authority.

London Stock Exchange

Invesco

REG - IVZ S&P Eql Wgt£ - Net Asset Value(s)

EQL Pharma AB held its annual general meeting on 21 August 2025, where several resolutions were adopted. The meeting approved the income statement and balance sheet, with no dividends for the financial year 2024/2025. Board members were discharged from liability, and new members were elected, including Raymond De Vré. The board's remuneration was set, and Deloitte AB was re-elected as auditor. A long-term incentive program for the CEO was approved, allowing for the issuance of up to 100,000 warrants, potentially diluting share capital by 0.34%.

Bulletin from the annual general meeting in EQL Pharma AB on 21 August 2025

EQL Pharma AB will hold its annual general meeting on August 21, 2025, in Lund. The Nomination Committee proposes a board of directors with six members, including re-elections for Anders Månsson, Christer Fåhraeus, Linda Neckmar, Per Svangren, and Nikunj Shah. Raymond De Vré is nominated as a new member, replacing Per Ollermark. Christer Fåhraeus is proposed for re-election as chairman.